Since the AKT/mTOR pathway is known to play a central role in the regulation of cell lipid metabolism, we hypothesised that blocking ACLY will reduce lipid synthesis and subsequently prevent tumour cell resistance to TKI therapy, enhancing its antitumor efficacy. The gene discussed is AKT1; the disease is neoplasm.